+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A phase II trial of taxotere 100 or 75 mg/m2 as 2nd line chemotherapy in patients with metastatic breast cancer with stratification according to prognosis factors



A phase II trial of taxotere 100 or 75 mg/m2 as 2nd line chemotherapy in patients with metastatic breast cancer with stratification according to prognosis factors



European Journal of Cancer 35(Suppl. 4): S320




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034314253

Download citation: RISBibTeXText


Related references

A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 134(2): 125-135, 2008

Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl. 2): 498-504, 2000

Preliminary data of a phase II randomized trial of taxotere and doxorubicin given simultaneously or sequentially as 1st line chemotherapy for metastatic breast cancer. European Journal of Cancer 35(Suppl. 4): S317, 1999

Taxotere phase III trial on the first-line treatment of metastatic breast cancer. Magyar Onkologia 44(1): 75-78, 2000

Phase II trial of doxorubicin and taxotere in patients with metastatic breast cancer. Breast Cancer Research & Treatment 57(1): 126, 1999

Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Research 26(3b): 2451-2456, 2006

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet. Oncology 15(11): 1269-1278, 2014

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. European Journal of Cancer 40(3): 352-357, 2004

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Annals of Oncology 5(6): 527-532, 1994

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer 6(6): 505-510, 2006

Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients. Oncology 73(3-4): 210-214, 2007

Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clinical Breast Cancer 12(5): 313-321, 2012

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer ChemoTherapy and Pharmacology 71(4): 1051-1057, 2013

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology 31(14): 1732-1739, 2013

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Annals of Oncology 21(2): 269-274, 2010